Focus will be on vaccine sales and pipeline news when Bavarian Nordic report is released, says bank
Attention will be paid to Bavarian Nordic's sales of the vaccines Rabipur/Rabavert and Encepur when it releases its financial report on Friday, says Danish bank Sydbank.
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen
Bavarian Nordic's sales of rabies vaccines Rabipur/Rabavert and Encepur, the company's tick-borne encephalitis vaccine, could take center stage when the pharmaceutical company releases its financial report tomorrow, says the Danish bank Sydbank.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian increases capital of USD 8.9m from selling shares
For subscribers
.jpg&w=384&q=75)
